Our findings highlight the potential of NAT10 as a therapeutic target for modulating mucosal immunity, particularly in the context of IgA-related pathologies such as IgA nephropathy and IBD (Bamias et al, 2023; Mantis et al, 2011; Stamellou et al, 2023). Here, CD79A is linked to inflammatory bowel disease.